Dividend for 2009
| $ | Pence | SEK | Payment date | |
|---|---|---|---|---|
| First interim dividend | 0.59 | 36.0 | 4.41 | 14 September 2009 |
| Second interim dividend | 1.71 | 105.4 | 12.43 | 15 March 2010 |
| Total | 2.30 | 141.4 | 16.84 |
$2.30 Dividend per Ordinary Share 2009
Our year in brief
Summary financial and operational information for 2009
Financial highlights
32.8bn Sales up 7% to $32,804 million ($31,601 million in 2008)
23% Core operating profit up 23% to $13,621 million ($10,958 million in 2008)
7.7bn Strong cash flows reduced net debt by $7,709 million resulting in net funds of $535 million
Sales
$m (+7%)
Net cash flow from operating activities $m
Sales growth
7% 2009
3% 2008
7% 2007
Core operating profit
$m (+23%)
Reported operating profit
$m (+24%)
Core gross margin $m (+10%)
Reported gross margin $m (+11%)
Core earnings per
Ordinary Share $ (+23%)
Reported basic earnings
per Ordinary Share $ (+22%)
Operational overview
Distributions to shareholders $m
| 2009 | 2008 | 2007 | |
|---|---|---|---|
| Dividends | 2,977 | 2,739 | 2,641 |
| Share re-purchases | - | 610 | 4,170 |
29% Crestor up 29% to $4,502 million
23% Symbicort up 23% to $2,294 million
4 Four major regulatory submissions
4 In-licensing/acquisition of four
late-stage projects
$1.6bn Annualised savings of $1.6 billion from restructuring
6% Top 6% in the sector in the Dow Jones Indexes
In brief
Sales
- Crestor sales were up 29% to $4,502 million; Symbicort up 23% to $2,294 million; Seroquel up 12% to
$4,866 million; and Arimidex up 7% to $1,921 million. Nexium sales fell by 1% to $4,959 million and Synagis sales fell by 12% to $1,082 million - Sales of Toprol-XL and H1N1 influenza (swine flu) vaccine in the US accounted for 3 percentage points of the global revenue growth
- Emerging Markets growth was 12%, accounting for 13% of total revenue
Pipeline developments include
- Four major regulatory submissions made
- Complete Response Letter submitted for fifth regulatory submission
- In-licensing/acquisition of four late-stage projects
- 89 projects in clinical development
Restructuring programme delivered annualised savings of $1.6 billion in 2009 and expanded to deliver further savings
Positioned in the top 6% in the sector in the Dow Jones World and STOXX (European) Indexes
Up to $1 billion in Ordinary Shares will be re-purchased by the Company during 2010
- Note: All growth rates are at CER.
